UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman

Melissa Holyoak Mark R. Meador

In the Matter of

Caremark Rx, LLC,

Zinc Health Services, LLC,

Express Scripts, Inc.,

Evernorth Health, Inc.,

Medco Health Services, Inc.,

Ascent Health Services LLC,

OptumRx, Inc.,

OptumRx Holdings, LLC, and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

COMPLAINT COUNSEL'S MOTION FOR LEAVE TO FILE A REPLY IN SUPPORT OF ITS MOTION TO LIFT THE STAY

Pursuant to Rule 3.22(d) of the Commission Rules of Practice, Complaint Counsel respectfully moves the Commission for leave to file the attached Reply in Support of Complaint Counsel's Motion to Lift the Stay (Ex. A).

Respondents' Opposition to Complaint Counsel's Motion to Lift the Stay states that Complaint Counsel "requested that the Commission set a hearing date without ever discussing the hearing date with Respondents." Respondents' Opp'n at 10. Complaint Counsel seeks leave to submit a brief Reply to correct the record. Leave is justified because at the time Complaint Counsel filed its initial Motion to Lift the Stay of Administrative Adjudication, it did not, and could not, anticipate the need to correct a material factual misrepresentation in Respondents' Opposition.

Dated: July 15, 2025 Respectfully submitted,

/s/ Rebecca L. Egeland

Rebecca L. Egeland

Federal Trade Commission 600 Pennsylvania Avenue, NW Washington, DC 20580 Tel: (202) 326-2990

Fax: (202) 326-3384 Email: regeland@ftc.gov

UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman

Melissa Holyoak Mark R. Meador

In the Matter of

Caremark Rx, LLC,

Zinc Health Services, LLC,

Express Scripts, Inc.,

Evernorth Health, Inc.,

Medco Health Services, Inc.,

Ascent Health Services LLC,

OptumRx, Inc.,

OptumRx Holdings, LLC, and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

MEET AND CONFER STATEMENT

Complaint Counsel sought Respondents' consent to file a Reply, but Respondents did not indicate whether they consented or opposed as of the time of this filing.

Dated: July 15, 2025 Respectfully submitted,

/s/ Rebecca L. Egeland

Rebecca L. Egeland

UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman

Melissa Holyoak Mark R. Meador

In the Matter of

Caremark Rx, LLC,

Zinc Health Services, LLC,

Express Scripts, Inc.,

Evernorth Health, Inc.,

Medco Health Services, Inc.,

Ascent Health Services LLC,

OptumRx, Inc.,

OptumRx Holdings, LLC, and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

[PROPOSED] ORDER

Upon consideration of Complaint Counsel's Motion for Leave to File a Reply in Support of its Motion to Lift the Stay,

IT IS HEREBY ORDERED that Complaint Counsel's Motion for Leave to File a Reply in Support of its Motion to Lift the Stay is **GRANTED**.

FEDERAL TRADE COMMISSION OFFICE OF THE SECRETA	ARY FILED 07/15/2025 OSCAR NO. 613713 -PAGE Page 5 of 16 *PUBLI
--	---

	By the Commission, Commissioner Holyoak recused.		
Dated:		April J. Tabor, Secretary	

EXHIBIT A

UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman

Melissa Holyoak Mark R. Meador

In the Matter of

Caremark Rx, LLC,

Zinc Health Services, LLC,

Express Scripts, Inc.,

Evernorth Health, Inc.,

Medco Health Services, Inc.,

Ascent Health Services LLC,

OptumRx, Inc.,

OptumRx Holdings, LLC, and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

$\frac{\text{COMPLAINT COUNSEL'S REPLY IN SUPPORT OF ITS MOTION TO LIFT THE}}{\text{STAY}}$

On July 14, 2025, Respondents filed an Opposition to Complaint Counsel's Motion to Lift the Stay. In their Opposition, Respondents wrongly assert that Complaint Counsel violated the stay order provision directing the parties to engage in good faith discussions on any proposed

timing on when the stay would be lifted and the ultimate hearing date. Respondents' Opp'n at 10. Complaint Counsel files this Reply to address Respondents' misrepresentation and correct the record.

As outlined in the Egeland Declaration, on June 23, 2025, Complaint Counsel reached out to Respondents to schedule a meet and confer about lifting the stay. In that email, Complaint Counsel explicitly invited Respondents "[p]er our agreement in the stay order. . . to meet and confer regarding the date on which a joint motion would request to lift the stay." Decl. ¶ 5; Decl. Ex. 1. During the discussions, the parties ultimately did not negotiate a specific date on which the Commission would lift the stay, because Respondents took the position that the stay should not be lifted at all until their yet-to-be filed motion to dismiss was resolved by the Commission. Decl. ¶ 7.

Complaint Counsel unquestionably acted in good faith and in accordance with the Commission Order and the parties' agreement. In any event, the lift-stay motion is now fully ripe for determination, and Complaint Counsel respectfully requests that the Commission lift the stay of the administrative adjudication.

¹ Respondents' Opposition also appears to exceed the page limitations provided in the Commission's Rules of Practice. 16 C.F.R. § 3.22(c) provides that "[m]emoranda in support of, or in opposition to, any other [non-dispositive] motion shall not exceed 2,500 words," including "headings, footnotes, and quotations," but Respondents' Opposition exceeds 2,800 words.

Dated: July 15, 2025 Respectfully submitted,

/s/ Rebecca L. Egeland

Rebecca L. Egeland

Federal Trade Commission 600 Pennsylvania Avenue, NW Washington, DC 20580 Tel: (202) 326-2990

Fax: (202) 326-3384 Email: regeland@ftc.gov

UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

COMMISSIONERS: Andrew N. Ferguson, Chairman

Melissa Holyoak Mark R. Meador

In the Matter of

Caremark Rx, LLC,

Zinc Health Services, LLC,

Express Scripts, Inc.,

Evernorth Health, Inc.,

Medco Health Services, Inc.,

Ascent Health Services LLC,

OptumRx, Inc.,

OptumRx Holdings, LLC, and

Emisar Pharma Services LLC,

Respondents.

Docket No. 9437

DECLARATION IN SUPPORT OF COMPLAINT COUNSEL'S REPLY IN SUPPORT OF ITS MOTION TO LIFT THE STAY

- 1. I have personal knowledge of the facts set forth in this declaration.
- 2. My name is Rebecca Egeland. I am an attorney admitted to practice law in the District of Columbia. I am employed by the Federal Trade Commission and am Complaint Counsel in this action.
- 3. On March 31, 2025, Complaint Counsel and Respondents jointly moved the Commission to stay the Part 3 Adjudicative Proceeding, given there were no sitting Commissioners

- able to participate in the matter at the time. The parties' Proposed Order sought to stay the proceeding for a minimum of 105 days, after which the stay could be lifted by the Commission upon motion by one or more of the parties.
- 4. On April 1, 2025, the Commission, pursuant the authority delegated to the General Counsel by 16 C.F.R. § 0.7(b), entered the Order Staying Administrative Adjudication. The Order included the parties' proposed language that "[t]he parties will engage in good faith discussions on any proposed timing on when the stay would be lifted and the ultimate hearing date." Order at 2.
- 5. On June 23, 2025, a little over three weeks before the end of the minimum stay period, I reached out to counsel for Respondents to meet and confer about lifting the stay. In my email, I stated our hope the parties could agree to file a joint motion to lift the stay, given the availability of sitting Commissioners able to participate in the matter. I further stated, "Per our agreement in the stay order, we are willing to meet and confer regarding the date on which a joint motion would request to lift the stay." Decl. Ex. 1, at 1.
- 6. Exhibit 1 attached to this declaration is an accurate and complete copy of the original email discussed in paragraph 5.
- 7. On July 2 and July 3, Complaint Counsel and Respondents met and conferred via video conference. During these discussions, Respondents conveyed their position that the stay of the Part 3 proceeding should not be lifted while their collateral constitutional challenge was pending in the Eighth Circuit and until a not-yet-filed motion to dismiss was decided by the Commission. Respondents further stated their intent to oppose a motion by Complaint Counsel to lift the stay. Complaint Counsel stated our intention to file a motion on Monday, July 7 to lift the stay.

8. On July 7, Complaint Counsel filed a Motion to Lift the Stay of Administrative Adjudication before the Commission.

I declare under penalty of perjury that the foregoing is true and correct. Executed on July 15, 2025, in Washington, DC.

/s/ Rebecca L. Egeland_ Rebecca L. Egeland

EXHIBIT 1

From: <u>Egeland, Rebecca</u>

To: CVSInsulinFTCMatter@wc.com; CVSInsulin@lists.dechert.com; RGH InsulinLit External@rulegarza.com; Service-

OptumRxInsulin@gibsondunn.com; EMainigi@wc.com; csinger@wc.com; SPyser@wc.com; KHoover@wc.com; Mike.Cowie@dechert.com; rani.habash@dechert.com; Howley@RuleGarza.com; Rule@RuleGarza.com;

Campbell@RuleGarza.com; Heipp@RuleGarza.com; Jennifer.Milici@wilmerhale.com; Perry.Lange@wilmerhale.com; john.otoole@wilmerhale.com; SLiversidge@gibsondunn.com;

MJPerry@gibsondunn.com; SHansell@gibsondunn.com; MParrott@gibsondunn.com Albert, Bradley Scott; Peay, Lauren; Black, Armine; InsulinFile2210114

Cc: Albert, Bradley Scott; Peay, Lauren; Black, Armine; InsulinFi

Subject: Docket No. 9437 - In the Matter of Caremark Rx, LLC, et al.

Date: Monday, June 23, 2025 10:33:53 AM

Greetings, all – As we are about three weeks out from the end of the minimum stay period in the Part 3 adjudicative proceeding, we are reaching out about a motion to lift the stay.

Given there are now sitting Commissioners able to participate in the matter and that we are not aware of any dispute Respondents have over the lawfulness of any current sitting Commissioner, we are hopeful we can agree to jointly move to lift the stay. Please let us know by COB on Wednesday if you will agree to lift the stay in the Part 3 proceeding. Per our agreement in the stay order, we are willing to meet and confer regarding the date on which a joint motion would request to lift the stay.

Best, Beckey

Rebecca L. Egeland

Attorney, Health Care Division Federal Trade Commission Phone: (202) 326-2990

Email: regeland@ftc.gov

CERTIFICATE OF SERVICE

I hereby certify that on July 15, 2025, I caused the foregoing document to be filed electronically using the FTC's E-Filing System, which will send notification of such filing to:

April Tabor Office of the Secretary Federal Trade Commission 600 Pennsylvania Avenue, NW Room H-113 Washington, DC 20580 ElectronicFilings@ftc.gov

Secretary of the Commission Clerk of the Court The Honorable Jay L. Himes Administrative Law Judge Federal Trade Commission 600 Pennsylvania Avenue, NW Room H-144 Washington, DC 20580 OALJ@ftc.gov

Administrative Law Judge

I also certify that I caused the foregoing document to be served via email to:

Enu Mainigi Craig D. Singer Steven M. Pyser WILLIAMS & CONNOLLY LLP 680 Maine Avenue SW Washington, DC 20024 emainigi@wc.com csinger@wc.com spyser@wc.com

Mike Cowie Rani A. Habash DECHERT LLP 1900 K Street NW Washington, DC 20006 mike.cowie@dechert.com rani.habash@dechert.com

Counsel for Respondents Caremark Rx LLC; Zinc Health Services, LLC Daniel J. Howley Charles F. (Rick) Rule Margot Campbell Justin T. Heipp RULE GARZA HOWLEY 901 7th Street NW, Suite 600 Washington, DC 20006 howley@rulegarza.com rule@rulegarza.com campbell@rulegarza.com heipp@rulegarza.com

Jennifer Milici
Perry A. Lange
John W. O'Toole
WILMERHALE
2100 Penn. Ave. NW
Washington, DC 20037
jennifer.milici@wilmerhale.com
perry.lange@wilmerhale.com
john.otoole@wilmerhale.com

Counsel for Respondents Express Scripts, Inc.; Evernorth Health, Inc.; Medco Health Services, Inc.; Ascent Health Services LLC Samuel Liversidge GIBSON, DUNN & CRUTCHER LLP 333 South Grand Avenue Los Angeles, CA 90071 SLiversidge@gibsondunn.com

Sophia A. Hansell
Michael J. Perry
Matthew C. Parrott
GIBSON, DUNN & CRUTCHER
LLP
1700 M Street NW
Washington, DC 20036
shansell@gibsondunn.com
mjperry@gibsondunn.com
mparrott@gibsondunn.com

Counsel for Respondents OptumRx, Inc.; OptumRx Holdings, LLC; Emisar Pharma Services LLC

/s/ Rebecca L. Egeland

Rebecca L. Egeland Federal Trade Commission Bureau of Competition 600 Pennsylvania Avenue, NW Washington, DC 20580 (202) 326-2290 regeland@ftc.gov